

**From:** [Quinn, Jack](#)  
**To:** [AGO - High Cost Prescription Drugs](#)  
**Cc:** [Gormanly, Vicky](#); [Quinn, Jack](#)  
**Subject:** Alexion Pharmaceuticals: Notice Pursuant to 18 V.S.A. § 4637  
**Date:** Friday, October 9, 2020 12:21:52 PM  
**Attachments:** [image002.png](#)  
[image003.png](#)

---

**EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.**

Office of the Attorney General of Vermont:

Please see the information below regarding the requirements of 18 V.S.A §4637. The date of launch is today, October 9, 2020.

Manufacturer Name	NDC	Name of Prescription Drug
Alexion Pharmaceuticals, Inc.	25682-025-01	ULTOMIRIS® (ravulizumab-cwvz)
Alexion Pharmaceuticals, Inc.	25682-028-01	ULTOMIRIS® (ravulizumab-cwvz)

Please reach out with any questions/comments.

Thank you.

-Jack Quinn

**Jack Quinn III**

Head of State Government Relations  
Corporate Affairs

| MOBILE +1 202.341.1824 |  
Alexion Pharmaceuticals, Inc.  
1455 Pennsylvania Ave., NW, Suite 510  
Washington, DC 20004

Rare Inspiration. Changing Lives.

---

CONFIDENTIALITY NOTICE -- This communication, including any attachments, is for the exclusive use of the intended recipient and may contain proprietary, confidential or privileged information. If you are not the intended recipient, any use, copying, disclosure, dissemination or distribution is strictly prohibited. If there is any reason to believe you are not the intended recipient, please notify the sender immediately by return email and delete this communication and destroy all copies. Thank you.